These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9654299)

  • 1. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Henry C; Wilson JA
    Lancet; 1998 Jun; 351(9120):1965-6. PubMed ID: 9654299
    [No Abstract]   [Full Text] [Related]  

  • 2. Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease.
    Sabaté M; Bosch A; Pedrós C; Figueras A
    Ann Pharmacother; 1999 Nov; 33(11):1228-9. PubMed ID: 10573327
    [No Abstract]   [Full Text] [Related]  

  • 3. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Harper J; Vieira B
    Lancet; 1998 Aug; 352(9127):578. PubMed ID: 9716090
    [No Abstract]   [Full Text] [Related]  

  • 4. Tolcapone for Parkinson's disease.
    Med Lett Drugs Ther; 1998 Jun; 40(1028):60-1. PubMed ID: 9629124
    [No Abstract]   [Full Text] [Related]  

  • 5. Tolcapone: COMT inhibition for the treatment of Parkinson's disease.
    Fahn S
    Neurology; 1998 May; 50(5 Suppl 5):S1-2. PubMed ID: 9591515
    [No Abstract]   [Full Text] [Related]  

  • 6. First COMT inhibitor approved for Parkinson's disease.
    Am J Health Syst Pharm; 1998 Mar; 55(6):524, 526. PubMed ID: 9544322
    [No Abstract]   [Full Text] [Related]  

  • 7. Catechol-O-methyltransferase inhibitors: new options for Parkinson's disease.
    Leicht MJ; Mitchell SD
    S D J Med; 1999 Aug; 52(8):295-7. PubMed ID: 10453205
    [No Abstract]   [Full Text] [Related]  

  • 8. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group.
    Waters CH; Kurth M; Bailey P; Shulman LM; LeWitt P; Dorflinger E; Deptula D; Pedder S
    Neurology; 1998 May; 50(5 Suppl 5):S39-45. PubMed ID: 9591521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease.
    Chong DJ; Suchowersky O; Szumlanski C; Weinshilboum RM; Brant R; Campbell NR
    Clin Neuropharmacol; 2000; 23(3):143-8. PubMed ID: 10895397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone].
    Arnold G; Kupsch A
    Nervenarzt; 2000 Feb; 71(2):78-83. PubMed ID: 10703007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
    Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects.
    Russ H; Müller T; Woitalla D; Rahbar A; Hahn J; Kuhn W
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Dec; 360(6):719-20. PubMed ID: 10619191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tolcapone in the management of Parkinson's disease].
    Pilipovich AA; Golubev VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(6):71-8. PubMed ID: 18688929
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
    Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I
    J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a-catechol-o-methyl transferase inhibitor.
    Iwuagwu CU; Riley D; Bonoma RA
    Am J Med; 2000 Apr; 108(6):517-8. PubMed ID: 10866587
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Benabou R; Waters C
    Expert Opin Drug Saf; 2003 May; 2(3):263-7. PubMed ID: 12904105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
    Limousin P; Pollak P; Pfefen JP; Tournier-Gervason CL; Dubuis R; Perret JE
    Clin Neuropharmacol; 1995 Jun; 18(3):258-65. PubMed ID: 8635184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of COMT inhibitors.
    Brooks DJ
    Neurology; 2004 Jan; 62(1 Suppl 1):S39-46. PubMed ID: 14718679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extending levodopa action: COMT inhibition.
    Martínez-Martín P; O'Brien CF
    Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive improvement during Tolcapone treatment in Parkinson's disease.
    Gasparini M; Fabrizio E; Bonifati V; Meco G
    J Neural Transm (Vienna); 1997; 104(8-9):887-94. PubMed ID: 9451720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.